318 related articles for article (PubMed ID: 23639651)
21. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
[TBL] [Abstract][Full Text] [Related]
24. Enantioselective synthesis of adamantylalanine and carboranylalanine and their incorporation into the proteasome inhibitor bortezomib.
de Bruin G; Mock ED; Hoogendoorn S; van den Nieuwendijk AM; Mazurek J; van der Marel GA; Florea BI; Overkleeft HS
Chem Commun (Camb); 2016 Mar; 52(21):4064-7. PubMed ID: 26894389
[TBL] [Abstract][Full Text] [Related]
25. Comparative mechanisms of action of proteasome inhibitors.
Wang M
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():19-24. PubMed ID: 25188479
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
28. Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit.
Stubba D; Bensinger D; Steinbacher J; Proskurjakov L; Salcedo Gómez Á; Schmidt U; Roth S; Schmitz K; Schmidt B
ChemMedChem; 2019 Dec; 14(23):2005-2022. PubMed ID: 31675179
[TBL] [Abstract][Full Text] [Related]
29. Indolo-phakellins as β5-specific noncovalent proteasome inhibitors.
Beck P; Lansdell TA; Hewlett NM; Tepe JJ; Groll M
Angew Chem Int Ed Engl; 2015 Feb; 54(9):2830-3. PubMed ID: 25581903
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and pharmacology of proteasome inhibitors.
Rentsch A; Landsberg D; Brodmann T; Bülow L; Girbig AK; Kalesse M
Angew Chem Int Ed Engl; 2013 May; 52(21):5450-88. PubMed ID: 23526565
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological properties of C-terminal vinyl ketone pseudotripeptides.
Franceschini C; Trapella C; Sforza F; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):560-4. PubMed ID: 22380778
[TBL] [Abstract][Full Text] [Related]
35. Novel oleanolic vinyl boronates: synthesis and antitumor activity.
Moreira VM; Salvador JA; Simões S; Destro F; Gavioli R
Eur J Med Chem; 2013 May; 63():46-56. PubMed ID: 23455056
[TBL] [Abstract][Full Text] [Related]
36. Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors.
Maréchal X; Pujol A; Richy N; Genin E; Basse N; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2012 Jun; 52():322-7. PubMed ID: 22440858
[TBL] [Abstract][Full Text] [Related]
37. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
38. Development of isoquinolinone derivatives as immunoproteasome inhibitors.
Ettari R; Iraci N; Di Chio C; Previti S; Danzè M; Zappalà M
Bioorg Med Chem Lett; 2022 Jan; 55():128478. PubMed ID: 34838650
[TBL] [Abstract][Full Text] [Related]
39. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
40. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
